Lenalidomide Exposed, Anti-CD38 MAb, Daratumumab+Pomalidomide+Dexamethasone (DPd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Pomalidomide+Dexamethasone (Pd), 1,2,3,>=4 prior line of therapy
### Instruction:
Identify the study with the following condition. 
### Input:
Lenalidomide Exposed, Anti-CD38 MAb, Daratumumab+Pomalidomide+Dexamethasone (DPd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Pomalidomide+Dexamethasone (Pd), 1,2,3,>=4 prior line of therapy 
### Output:
Popular Name is APOLLO, Study ID is NCT03180736